| ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More | Alex Lash | 06/05/19 | National |
| For CAR-T Cancer Fighters in the Real World, Two Roads Diverge | Alex Lash | 01/03/19 | National |
| Drug Developer Kiromic Declines San Antonio’s Cash Offer for HQ Move | David Holley | 07/17/18 | Texas |
| Eying Clinical Trials, Shattuck Labs Adds $46M for Immunotherapy R&D | David Holley | 05/30/18 | Texas |
| Immunotherapy Biotech Kiromic Considers San Antonio Move for Cash | David Holley | 05/24/18 | Texas |
| Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR-T Cells | Alex Lash | 04/03/18 | San Francisco |
| Bellicum Reveals Brain Injuries, FDA Halt on Lead T-Cell Product | Alex Lash | 01/31/18 | Texas |
| Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & More | Alex Lash | 01/26/18 | National |
| Kite Nabs First Adult CAR-T Approval With Notable Uptick Of Cures | Alex Lash | 10/18/17 | National |
| Palleon Lands $48M to Develop New Type of Checkpoint Cancer Drug | David Holley | 10/04/17 | Boston |
| Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000 | Alex Lash | 08/30/17 | National |
| Acer Therapeutics Announces Reverse Merger With Houston’s Opexa | Angela Shah | 07/05/17 | Texas |
| ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More | Ben Fidler | 12/06/16 | National |
| Two More Deaths In Trial Halt Juno’s Top CAR-T Treatment Again | Alex Lash | 11/23/16 | Seattle |
| All In One Place: A New Immuno-Oncology Trial Resource | Alex Lash | 10/19/16 | National |
| Novartis Disbands T Cell Group But Promises To Press Ahead In CAR-T Race | Alex Lash | 08/31/16 | National |
| War, Surgery, and Cancer Vaccines: Meet San Antonio’s George Peoples | David Holley | 08/19/16 | Texas |
| With New Name and $86M, Tioma To Explore Anti-CD47 Cancer Therapy | David Holley | 08/16/16 | San Francisco |
| With Celgene Deal, Jounce Lands $261M And a “Trusting Partner” | David Holley | 07/19/16 | Boston |
| West Coast Bio Roundup: UCLA Cashes In, BioMarin Tries Again & More | Alex Lash | 03/04/16 | San Francisco |
| JLabs @ TMC Opens Houston Campus, Home to 21 Biotech Startups | Angela Shah | 03/02/16 | Texas |
| Bayer, CRISPR Therapeutics Form $335M+ Gene Editing Venture | Ben Fidler | 12/21/15 | Boston |
| What Three Biotechs Could Tell Us About The Pfizer-Allergan Merger | Alex Lash | 12/01/15 | National |
| Small Molecules: The Silent Majority of Pharmaceutical Pipelines | Yuval Cohen | 11/23/15 | Boston |
| With Termeer Aboard, Artax Tries New Attack On Autoimmune Disease | Alex Lash | 09/22/15 | Boston |
| Reality Check: Cancer Experts Discuss Hurdles Facing CAR-T Therapy | Ben Fidler | 09/18/15 | National |
| With New Tools, Adaptive Bio Ready To Bolt Together A Drug Business | Alex Lash | 08/20/15 | Seattle |
| East Coast Biotech Roundup: Biogen, Epizyme, Armored CARS, & More | David Holley | 07/13/15 | Boston |
| After Celgene Deal, Juno Revs Armored CAR For Ovarian Cancer Trial | Alex Lash | 07/10/15 | Seattle |
| West Coast Biotech Roundup: Juno, UCSD v. USC, Natera, LSDF & More | Alex Lash | 07/06/15 | Seattle |
